Intrabiliary rapamycin may slow progression of primary sclerosing cholangitis

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 4, 2012, Pages 490-

  Karaahmet, F ^a   Kilincalp, S ^a   Altinbas, A ^a   Coban, S ^a   Yuksel, O ^a  

^a Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DOCOSAHEXAENOIC ACID; RAPAMYCIN;

ANTIINFLAMMATORY ACTIVITY; BILIARY CIRRHOSIS; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; LETTER; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RESTENOSIS; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT RESPONSE;

CHOLANGITIS, SCLEROSING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS;

EID: 84856057189     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04974.x     Document Type: Letter

References (7)

1. Martin CR, Blanco PG, Keach J, et al,. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 2012; 35: 255-65.
2. Tischendorf JJ, Hecker H, Krüger M, et al,. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102: 107-14. (Pubitemid 46072050)
3. Broome U, Hultcrantz R, Scheynius A,. Lack of concomitant expression of ICAM-1 and HLA-DR on bile duct cells from patients with primary sclerosing cholangitis and primary biliary cirrhosis. Scand J Gastroenterol 1993; 28: 126-30. (Pubitemid 23051779)
4. Angulo P, Lindor KD,. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-32. (Pubitemid 29300604)
5. Özdemir BH, Özdemir AA, Erdal R, et al,. Rapamycin prevents interstitial fibrosis in renal allografts through decreasing angiogenesis and inflammation. Transplant Proc 2011; 43: 524-6.
6. Biecker E, De Gottardi A, Neef M, et al,. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005; 313: 952-61. (Pubitemid 40726999)
7. Morice MC, Serruys PW, Sousa JE, et al,. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80. (Pubitemid 34586912)